Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

Next Previous
X
Search
Trial Profile

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Feb 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carbetocin (Primary)
  • Indications Prader-Willi syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms COMPASS PWS
  • Sponsors Acadia Pharmaceuticals

    • Most Recent Events

    • 14 Jan 2025 According to an Acadia Pharmaceuticals media release, enrollment of the last patient anticipated in the fourth quarter of 2025, followed by top-line results announcement in the first half of 2026.
    • 30 Nov 2023 According to Acadia Pharmaceuticals media release, Shawn McCandless, MD, Chair, Department of Genetics and Metabolism, Children's Hospital Colorado and investigator of this COMPASS PWS study.
    • 30 Nov 2023 Status changed to recruiting, according to Acadia Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top